Navigation Links
Neurelis Enters into Option and Merger Agreement with Biotie Therapies
Date:6/4/2013

SAN DIEGO, June 4, 2013 /PRNewswire/ -- Neurelis, Inc. ("Neurelis") today announced an agreement with Biotie Therapies Corp. ("Biotie") to further develop NRL-1 (intranasal diazepam) and provide Biotie with the exclusive option, but not the obligation, to acquire all outstanding shares of Neurelis.

Under the terms of the option and merger agreement between Biotie and Neurelis, Biotie will make a payment of US$1.0 million to Neurelis for the exclusive option to acquire all of the outstanding shares of Neurelis.  During the option period, Biotie will conduct the development program for NRL-1 and work with Neurelis on advancing the program with the FDA in preparation for the pivotal clinical work required for NDA submission.  Under the terms of the option and merger agreement, if the option is exercised and the merger is consummated, Biotie will make a payment of US$8.75 million, subject to certain adjustments, to be paid in new ordinary shares of Biotie.  Stockholders of Neurelis will also be eligible to receive additional milestone payments based on certain regulatory and commercial milestones. 

"We are excited at the prospect of working with Biotie on the continued development of NRL-1, with the goal of bringing this promising and unique therapy to patients with epilepsy" stated Craig C. Chambliss , President and Chief Executive Officer of Neurelis.  "The proven success of Biotie's development efforts and the potential of an intranasal diazepam program with unmatched bioavailability and a well-tolerated safety profile could significantly benefit patients who experience acute repetitive seizures."

About NRL-1

NRL-1 (intranasal diazepam) is a proprietary formulation of diazepam delivered via a commercially available nasal sprayer.  It is being developed for the management of patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity.  There are over 2.7 million people with epilepsy in the United States with approximately 200,000 new patients diagnosed each year.  It is estimated that between 30% and 40% of these patients are uncontrolled on oral therapy and are at-risk for acute breakthrough seizures.  Studies have shown that prolonged or repetitive seizures can cause neurological damage and dramatically increase the risk of changes in neuropsychological function or even death.

Presently, the only product approved in the United States for the treatment of acute repetitive seizures outside of the hospital setting is a rectally administered formulation of diazepam called Diastat®.  Because of its rectal mode of administration, Diastat® has been primarily relegated to use in younger pediatric patients (usually less than 10 years of age).  The majority of patients with acute repetitive seizures however, are currently seen in emergency rooms and treated with intravenous benzodiazepines.  Most of these patients are admitted to the hospital.  Intranasal diazepam has the potential to provide a superior alternative to either rectal administration of Diastat® or the need to visit the emergency room for intravenous administration of drugs.

About Biotie

Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence (addiction) and post-traumatic stress disorder), and inflammatory and fibrotic liver disease. The company has a strong and balanced development portfolio with several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie's products address diseases with high unmet medical need and significant market potential.  Biotie ordinary shares are listed on NASDAQ OMX Helsinki Ltd.

About Neurelis

Neurelis, Inc. is a privately-held San Diego-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system (CNS) market.  Neurelis leverages expertise in the development and commercialization of CNS compounds and strong relationships with leading researchers and clinicians in these markets to advance unique product candidates to address significant unmet medical needs.

Contact: 

Craig C. Chambliss, President and CEO


858-531-5859


Email: cchambliss@neurelis.com


'/>"/>
SOURCE Neurelis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
3. CyberKnife System and the da Vinci Surgical System in Concord Medical Centers Achieve Over RMB 10 Million in Medical Revenue Since Opening in February
4. 3 Pediatric Centers that Offer SynCardia Total Artificial Heart Named in Top 10 for "Best Childrens Hospitals"
5. Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress Instruments For A Four-Year Drug Clinical Trial
6. The Galien Foundation Announces Roster of Luminary Presenters for Third Galien Forum; Program Highlights Include CEO Panel, Panel on Alzheimers Disease Innovation, Nobel Laureate Elie Wiesel
7. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
8. Spine Pain Management Opens Two Additional Affiliate Diagnostic Centers in Florida
9. Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
10. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
11. Winner Medical Enters into Definitive Merger Agreement with Winner Holding Limited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Research and Markets has announced the addition of the ... to 2021" report to their offering. ... , , The immunohistochemistry (IHC) ... a CAGR of 7.3% during the forecast period of 2016 to 2021. ... rapidly increasing geriatric population across the globe are the primary driving the ...
(Date:12/7/2016)... 7, 2016  Palatin Technologies, Inc. ("Palatin") (NYSE ... a previously disclosed underwritten public offering of units ... as sole book-running manager, Roth Capital Partners acted ... as co-manager for the offering. "This ... net proceeds, allowing us to continue advancing bremelanotide ...
(Date:12/7/2016)... , Dec. 7, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Janus Kinase 3 (JAK3) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... AlignLife clinics nationwide ... Many children are not fortunate enough to receive bountiful gifts wrapped tightly under a ... can bring to the children of the world. , In exchange for generous donations, ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
Breaking Medicine News(10 mins):